Advertisement

Lipitor Patent Expires

The pharmaceutical darling that has brought billions in revenue to Pfizer over the past 15 years will now share the shelves with its generic competitors.

By | November 30, 2011

DREAMSTIME, KATERYNA PORTOKHOVA

Pfizer’s monopoly over the blockbuster cholesterol-reducing molecule atorvastatin, trade name Lipitor, ends today (November 30) with the expiration of the patent that has brought the company over $100 billion since the drug was introduced in 1997. While the introduction of generic alternatives into the market may pose a relief for consumer pockets, the expiration of patents for Lipitor and other drugs in the next three years may result in a loss of about $95 billion for big drug companies, Nature reported.

Atorvastatin was first synthesized in 1985 by Bruce D. Roth, a chemist working at Parke-Davis Warner-Lambert Company (now Pfizer). Modeled after naturally occurring compounds known as statins, atorvastatin reduces blood cholesterol by inhibiting a key liver enzyme involved in the production of cholesterol. When Lipitor splashed into the market in 1997, it was celebrated as a marked improvement over available drugs due to its high efficiency and few side effects.

But the past decade has not boded well for pharmaceutical companies, as investors have come to realize that success stories such as Lipitor’s are more the exception than the norm. As a result, big companies such as Pfizer have drastically reduced their research and development budgets, and many are shying away from possible blockbusters and turning toward more niche drugs, according to Nature.

Generic Lipitor, produced by New Jersey-based Watson Pharmaceuticals Inc., will be available as early as December 5, with other companies following suit pending FDA clearance, Bloomberg reported.

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement
RayBiotech
RayBiotech

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Teknova
Teknova
Advertisement
Life Technologies